Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile
Articolo
Data di Pubblicazione:
2010
Citazione:
Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile / S. Giovannini, M. Cesari, E. Marzetti, C. Leeuwenburgh, M. Maggio, M. Pahor. - In: THE JOURNAL OF NUTRITION, HEALTH & AGING. - ISSN 1279-7707. - 14:6(2010 Jun), pp. 457-460. [10.1007/s12603-010-0036-7]
Abstract:
OBJECTIVES:
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease.
DESIGN:
Data are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial.
SETTING:
Participants were recruited from the communities of Winston Salem, NC, and Greensboro, NC.
PARTICIPANTS:
Subjects > or = 55 years old with high cardiovascular disease risk profile.
INTERVENTION:
The intervention consisted of 6-month administration of fosinopril vs. placebo.
MEASUREMENTS:
Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits. Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired ttests.
RESULTS:
The mean age of participants (47% women) was 66.5 (standard deviation 7.2) years. Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported.
CONCLUSIONS:
A six-month treatment with fosinopril increases systemic levels of total IGF-1 and IGFBP-3 in older adults with high cardiovascular risk profile. This may represent a potential biological explanation to the beneficial effects of ACE-inhibition on stroke, ischemic heart disease and insulin resistance.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Female; Fosinopril; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Middle Aged; Risk Factors
Elenco autori:
S. Giovannini, M. Cesari, E. Marzetti, C. Leeuwenburgh, M. Maggio, M. Pahor
Link alla scheda completa: